| INVITED REVIEW |
|
| Year : 2019 | Volume
: 21
| Issue : 3 | Page : 249-252 |
|
|
Impact of taxanes on androgen receptor signaling
Shanshan Bai1, Bryan Y Zhang2, Yan Dong3
1 College of Life Sciences, Jilin University, Changchun 130012, China
Department of Structural and Cellular Biology, Tulane University School of Medicine, Tulane Cancer Center, New Orleans, LA 70112, USA
Lusher Charter School, New Orleans, LA 70115, USA
Correspondence Address:
Yan Dong
Department of Structural and Cellular Biology, Tulane University School of Medicine, Tulane Cancer Center, New Orleans, LA 70112, USA
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/aja.aja_37_18
|
|
|
The development and progression of metastatic castration-resistant prostate cancer is the major challenge in the treatment of advanced prostate cancer. The androgen receptor signaling pathway remains active in metastatic castration-resistant prostate cancer. Docetaxel and cabazitaxel are the first- and second-line chemotherapy, respectively, for patients with metastatic castration-resistant prostate cancer. These two taxanes, in general, function by (i) inhibiting mitosis and inducing apoptosis and (ii) preventing microtubule-dependent cargo trafficking. In prostate cancer, taxanes have been reported to inhibit the nuclear translocation and activity of the androgen receptor. However, whether this is attainable or not clinically remains controversial. In this review, we will provide a comprehensive view of the effects of taxanes on androgen receptor signaling in prostate cancer.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
